Ludwig H, Fritz E, Kotzmann H, Gisslinger H
II. Medizinische Universitätsklinik Wien.
Onkologie. 1990 Feb;13(1):46-9. doi: 10.1159/000216719.
Anemia of malignancy is a complication of neoplastic disease which causes impairing symptoms and often requires blood transfusions. In this clinical trial, we have treated 13 patients suffering from chronic anemia of malignancy and multiple myeloma with recombinant human erythropoietin (rHuEPO) three times a week. Eleven patients responded to the treatment by appropriate increases of their hemoglobin levels and the eventual correction of the anemic state, one non-responding patient had to terminate the treatment early because of transfusion requirements. Under rHuEPO therapy, the evaluated parameters of iron metabolism indicated the enhanced synthesis of hemoglobin. The symptoms of anemia subsided in the responding patients and most of them reported a hightened subjective sense of well-being. No adverse side effects, particularly no episodes of hypertension, were observed in any patient.
恶性肿瘤性贫血是肿瘤疾病的一种并发症，会引发损害性症状，且常常需要输血治疗。在这项临床试验中，我们对13名患有慢性恶性肿瘤性贫血和多发性骨髓瘤的患者，每周三次使用重组人促红细胞生成素（rHuEPO）进行治疗。11名患者对治疗有反应，血红蛋白水平适当升高，最终贫血状态得到纠正，1名无反应的患者因需要输血而不得不提前终止治疗。在rHuEPO治疗下，铁代谢的评估参数表明血红蛋白合成增强。有反应的患者贫血症状消退，他们中的大多数人报告主观幸福感增强。未观察到任何患者有不良副作用，尤其是没有高血压发作的情况。
